BridgeBio Pharma, Inc. (BBIO) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $67.68, but acceptable to hold if already in. Reasons: Concentration risk — Product: Attruby and Beyonttra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0).
BridgeBio Pharma is a commercial-stage biopharmaceutical company with Attruby (acoramidis) approved for ATTR-CM, generating $362.4 million in U.S. net product revenues in 2025, plus $105M in Beyonttra license/services revenue from Europe and Japan. Multiple Phase 3 programs... Read more
Hold if already holding. Not a fresh buy at $67.68, but acceptable to hold if already in. Reasons: Concentration risk — Product: Attruby and Beyonttra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: RSI 54 mid-range, Bollinger mid-band. Mixed signals. Hold existing position. Score 5.6/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — BridgeBio Pharma, Inc.
Latest news
- NEWS BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus — GuruFocus positive
- NEWS BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha — Seeking Alpha positive
- NEWS Why BridgeBio Pharma (BBIO) Is Down 6.4% After Attruby’s Faster-Than-Expected Commercial Ramp - And What's Next - simply — simplywall.st negative
- NEWS Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Wave Life Sciences (WVE) - The Globe and Mail — The Globe and Mail positive
- NEWS BBIO Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus — GuruFocus positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAttruby and Beyonttra10-K Item 1A: 'Our business is substantially dependent on the commercial success of Attruby and Beyonttra'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $67.68, but acceptable to hold if already in. Reasons: Concentration risk — Product: Attruby and Beyonttra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: RSI 54 mid-range, Bollinger mid-band. Mixed signals. Hold existing position. Target $92.44 (+36.6%), stop $62.94 (−7.5%), A.R:R 4.3:1. Score 5.6/10, moderate confidence.
Take-profit target: $92.44 (+36.6% upside). Target $92.44 (+36.6%), stop $62.94 (−7.5%), A.R:R 4.3:1. Stop-loss: $62.94.
Concentration risk — Product: Attruby and Beyonttra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0); Consecutive earnings misses (3).
BridgeBio Pharma, Inc. trades at a P/E of N/A (forward 203.3). TrendMatrix value score: 4.1/10. Verdict: Hold.
29 analysts cover BBIO with a consensus score of 4.2/5. Average price target: $103.
What does BridgeBio Pharma, Inc. do?BridgeBio Pharma is a commercial-stage biopharmaceutical company with Attruby (acoramidis) approved for ATTR-CM,...
BridgeBio Pharma is a commercial-stage biopharmaceutical company with Attruby (acoramidis) approved for ATTR-CM, generating $362.4 million in U.S. net product revenues in 2025, plus $105M in Beyonttra license/services revenue from Europe and Japan. Multiple Phase 3 programs target 2026 BLA submissions including navenibart (HAE), infigratinib (achondroplasia), and encaleret (ADH1). The business is substantially dependent on Attruby and Beyonttra for near-term revenues.